PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Vered Stearns

Cornell University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines1

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · JOURNAL ARTICLE

Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer

Journal of Clinical Oncology

A narrative review synthesizing randomized trial evidence and recent regulatory approvals to propose a risk-adapted treatment framework for HER2-positive early-stage breast cancer, not reporting original trial data.

Expert GuidanceSam O. Kleeman Breast Cancer Treatment Studies Vered Stearns

Reported

Carboplatin omission feasibilitycomparable pathological complete response r…

FDA approval statusfam-trastuzumab deruxtecan-nxki approved fo…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support